Eli Lilly Acquires Ventyx Biosciences for $1.2 Billion, Strategizing Beyond Weight Management Drugs
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 17 2026
0mins
Should l Buy LLY?
Source: Fool
- Acquisition Strategy: Eli Lilly's acquisition of Ventyx Biosciences for $1.2 billion in cash enhances its drug pipeline focused on neurodegenerative and cardiovascular diseases, thereby reducing reliance on the weight management market.
- Drug Potential: Ventyx's VTX3232 has shown promise in reducing cardiovascular risk in obese patients, and when paired with semaglutide, it significantly lowers inflammation and cardiovascular risk markers, indicating its potential use in high-risk patients.
- Market Reaction: Following the acquisition announcement, Eli Lilly's stock price rose, reflecting market approval of its strategy to expand its drug pipeline, with future data releases expected to have minimal impact on stock fluctuations.
- Ongoing Investments: Eli Lilly has strengthened its portfolio through multiple acquisitions and licensing agreements, including SiteOne Therapeutics and Verve Therapeutics, demonstrating its commitment to expanding in the cardiovascular and oncology sectors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 874.000
Low
950.00
Averages
1192
High
1500
Current: 874.000
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly Expected to Report Strong Q1 Earnings Growth
- Earnings Expectations: Eli Lilly is projected to report Q1 EPS of $6.85 with a 40.3% year-over-year revenue increase to $17.86 billion, indicating strong performance in the obesity treatment market that could drive stock price up.
- Drug Catalysts: Analysts believe that obesity drugs Mounjaro and Zepbound will anchor Lilly's medium-term growth, while the approval of Foundayo and the $7 billion acquisition of Kelonia Therapeutics serve as near-term catalysts that may enhance market confidence.
- Management Guidance: Analyst Stephen Ayers is keenly awaiting management's reaffirmation of the 2026 revenue guidance, as maintaining the current outlook may signal strong market performance for Foundayo, whereas a revision to the lower end could indicate pricing erosion or lagging uptake.
- Market Dynamics: Despite a more than 17% decline in Eli Lilly's stock this year, the company has beaten EPS and revenue estimates 100% of the time over the past two years, maintaining a positive outlook for future performance.
See More
India's IT Sector Faces Employment Crisis Amid AI Disruption
- Deepening Employment Crisis: Bernstein warns that the rise of AI may lead to a reduction in high-quality jobs in India's IT sector, affecting the income and consumption capacity of 10 to 15 million employees in IT services and outsourcing, thereby threatening the foundation of national economic growth.
- Shifting Hiring Trends: Net hiring by India's top five IT companies dropped by around 7,000 in FY26, with TCS planning to hire only 25,000 fresh graduates compared to an average of 40,000 over the past three years, indicating a diminishing reliance on large-scale recruitment in the industry.
- Skills Gap Challenge: While the Indian government emphasizes
See More
US Stock Update: Tech Stocks and Economic Data Insights
- Eli Lilly's Decline: Eli Lilly's stock has dropped about 17% over the past three months and is down 25% from its January peak, indicating pressure on the company amidst competitive market conditions that may affect investor confidence moving forward.
- Caterpillar's Strong Growth: Caterpillar shares surged approximately 22% in the last three months and 163% over the past year, benefiting from the data center construction boom, showcasing its strategic advantage in infrastructure investments.
- Amazon's Cloud Service Growth: Amazon reported a 28% growth in its cloud services in its latest earnings report, with shares rising 3% in after-hours trading and approximately 18% year-to-date, reflecting its sustained strong performance in the cloud computing market.
- Bond Yield Changes: The 1-month Treasury bill yield stands at 3.64%, while the 10-year Treasury yield is at 4.43%, indicating shifts in market expectations regarding future economic growth, which may influence investors' asset allocation strategies.
See More
Viking Therapeutics Reports Q1 Net Loss of $158.3 Million
- Deteriorating Financials: Viking Therapeutics reported a Q1 net loss of $158.3 million, or $1.37 per share, which is more than triple the $45.6 million loss from the same period last year, indicating a significant increase in cash burn as the company rapidly advances its clinical programs.
- Surging R&D Expenses: Research and development costs skyrocketed to $150.2 million from $41.4 million a year earlier, driven by clinical trial expenses, manufacturing scale-up, and personnel costs, reflecting the company's substantial investment in its obesity and metabolic disease pipeline.
- Declining Cash Reserves: As of March 31, 2026, Viking's cash and short-term investments totaled $603 million, down from $706 million at the end of 2025, yet still providing ample runway for its clinical programs.
- Clinical Trial Advancements: The company plans to launch a late-stage trial for the oral formulation of VK2735 in Q4 2026, while both late-stage trials for the subcutaneous version are fully enrolled ahead of schedule, showcasing the company's proactive strategy in the obesity treatment market.
See More
Stocks Pull Back as Oil Prices Rise, Impacting Market Sentiment
- Rising Oil Prices: West Texas Intermediate crude surpassed $107 per barrel and Brent crude exceeded $119, leading to a rise in U.S. gasoline prices to nearly $4.23 per gallon, up from $4.18 on Tuesday, indicating heightened market concerns over inflation.
- Fed Policy Divergence: The Federal Reserve maintained interest rates at its latest meeting, but for the first time, four officials dissented, reflecting internal disagreements on future monetary policy, which could influence market expectations regarding interest rate movements.
- Boeing Stock Decline: Boeing shares fell after Airbus secured a $21.37 billion order for 102 A320neo jets from China Southern Airlines, highlighting increased competitive pressure on Boeing in the Chinese market, although there remains potential for significant future orders.
- Earnings Season Approaches: Major companies like Amazon, Alphabet, Meta, and Microsoft are set to report earnings, with market focus on their performance regarding AI demand, supply constraints, and capital expenditures, with expectations that the four will collectively spend at least $608 billion this year to maintain competitiveness in the AI sector.
See More
Eli Lilly's Foundayo Launch Insights Awaited Amid Sales Uncertainty
- Launch Delays: Eli Lilly's weight-loss pill Foundayo launched in the U.S. in early April, but its absence from first-quarter financials leaves investors uncertain about its market performance, with analysts suggesting initial sales may lag behind Novo Nordisk's Wegovy.
- Insufficient Sales Data: Investors generally believe that 5 to 6 weeks of prescription data are needed to accurately assess Foundayo's sales trajectory, with BMO Capital Markets analysts noting that CEO Dave Ricks' comments will be crucial, highlighting the market's focus on the new drug.
- International Market Pressure: While Lilly's Mounjaro saw sales double in India, the introduction of cheaper generic versions of Novo's Wegovy by local manufacturers is expected to pressure demand, particularly as the mix of pricing and demand for these drugs in global markets becomes a focal point for investors.
- Policy Uncertainty: The uncertainty surrounding U.S. reimbursement policies for obesity drugs has heightened investor concerns, especially following the delay of the Medicare pilot program, which may impact Lilly's pricing strategies and market share in the lucrative U.S. market.
See More
Eli Lilly Expected to Report Strong Q1 Earnings Growth
- Earnings Expectations: Eli Lilly is projected to report Q1 EPS of $6.85 with a 40.3% year-over-year revenue increase to $17.86 billion, indicating strong performance in the obesity treatment market that could drive stock price up.
- Drug Catalysts: Analysts believe that obesity drugs Mounjaro and Zepbound will anchor Lilly's medium-term growth, while the approval of Foundayo and the $7 billion acquisition of Kelonia Therapeutics serve as near-term catalysts that may enhance market confidence.
- Management Guidance: Analyst Stephen Ayers is keenly awaiting management's reaffirmation of the 2026 revenue guidance, as maintaining the current outlook may signal strong market performance for Foundayo, whereas a revision to the lower end could indicate pricing erosion or lagging uptake.
- Market Dynamics: Despite a more than 17% decline in Eli Lilly's stock this year, the company has beaten EPS and revenue estimates 100% of the time over the past two years, maintaining a positive outlook for future performance.
See More
India's IT Sector Faces Employment Crisis Amid AI Disruption
- Deepening Employment Crisis: Bernstein warns that the rise of AI may lead to a reduction in high-quality jobs in India's IT sector, affecting the income and consumption capacity of 10 to 15 million employees in IT services and outsourcing, thereby threatening the foundation of national economic growth.
- Shifting Hiring Trends: Net hiring by India's top five IT companies dropped by around 7,000 in FY26, with TCS planning to hire only 25,000 fresh graduates compared to an average of 40,000 over the past three years, indicating a diminishing reliance on large-scale recruitment in the industry.
- Skills Gap Challenge: While the Indian government emphasizes
See More
US Stock Update: Tech Stocks and Economic Data Insights
- Eli Lilly's Decline: Eli Lilly's stock has dropped about 17% over the past three months and is down 25% from its January peak, indicating pressure on the company amidst competitive market conditions that may affect investor confidence moving forward.
- Caterpillar's Strong Growth: Caterpillar shares surged approximately 22% in the last three months and 163% over the past year, benefiting from the data center construction boom, showcasing its strategic advantage in infrastructure investments.
- Amazon's Cloud Service Growth: Amazon reported a 28% growth in its cloud services in its latest earnings report, with shares rising 3% in after-hours trading and approximately 18% year-to-date, reflecting its sustained strong performance in the cloud computing market.
- Bond Yield Changes: The 1-month Treasury bill yield stands at 3.64%, while the 10-year Treasury yield is at 4.43%, indicating shifts in market expectations regarding future economic growth, which may influence investors' asset allocation strategies.
See More
Viking Therapeutics Reports Q1 Net Loss of $158.3 Million
- Deteriorating Financials: Viking Therapeutics reported a Q1 net loss of $158.3 million, or $1.37 per share, which is more than triple the $45.6 million loss from the same period last year, indicating a significant increase in cash burn as the company rapidly advances its clinical programs.
- Surging R&D Expenses: Research and development costs skyrocketed to $150.2 million from $41.4 million a year earlier, driven by clinical trial expenses, manufacturing scale-up, and personnel costs, reflecting the company's substantial investment in its obesity and metabolic disease pipeline.
- Declining Cash Reserves: As of March 31, 2026, Viking's cash and short-term investments totaled $603 million, down from $706 million at the end of 2025, yet still providing ample runway for its clinical programs.
- Clinical Trial Advancements: The company plans to launch a late-stage trial for the oral formulation of VK2735 in Q4 2026, while both late-stage trials for the subcutaneous version are fully enrolled ahead of schedule, showcasing the company's proactive strategy in the obesity treatment market.
See More
Stocks Pull Back as Oil Prices Rise, Impacting Market Sentiment
- Rising Oil Prices: West Texas Intermediate crude surpassed $107 per barrel and Brent crude exceeded $119, leading to a rise in U.S. gasoline prices to nearly $4.23 per gallon, up from $4.18 on Tuesday, indicating heightened market concerns over inflation.
- Fed Policy Divergence: The Federal Reserve maintained interest rates at its latest meeting, but for the first time, four officials dissented, reflecting internal disagreements on future monetary policy, which could influence market expectations regarding interest rate movements.
- Boeing Stock Decline: Boeing shares fell after Airbus secured a $21.37 billion order for 102 A320neo jets from China Southern Airlines, highlighting increased competitive pressure on Boeing in the Chinese market, although there remains potential for significant future orders.
- Earnings Season Approaches: Major companies like Amazon, Alphabet, Meta, and Microsoft are set to report earnings, with market focus on their performance regarding AI demand, supply constraints, and capital expenditures, with expectations that the four will collectively spend at least $608 billion this year to maintain competitiveness in the AI sector.
See More
Eli Lilly's Foundayo Launch Insights Awaited Amid Sales Uncertainty
- Launch Delays: Eli Lilly's weight-loss pill Foundayo launched in the U.S. in early April, but its absence from first-quarter financials leaves investors uncertain about its market performance, with analysts suggesting initial sales may lag behind Novo Nordisk's Wegovy.
- Insufficient Sales Data: Investors generally believe that 5 to 6 weeks of prescription data are needed to accurately assess Foundayo's sales trajectory, with BMO Capital Markets analysts noting that CEO Dave Ricks' comments will be crucial, highlighting the market's focus on the new drug.
- International Market Pressure: While Lilly's Mounjaro saw sales double in India, the introduction of cheaper generic versions of Novo's Wegovy by local manufacturers is expected to pressure demand, particularly as the mix of pricing and demand for these drugs in global markets becomes a focal point for investors.
- Policy Uncertainty: The uncertainty surrounding U.S. reimbursement policies for obesity drugs has heightened investor concerns, especially following the delay of the Medicare pilot program, which may impact Lilly's pricing strategies and market share in the lucrative U.S. market.
See More
